Effectiveness of continuous pharmacist intervention at maintaining dose intensity in postoperative adjuvant S-1 chemotherapy for gastric cancer: a multicentre retrospective study Authors: Toshinobu Hayashi, Makiko Go, Kenji Kawasumi, Kazuyoshi Kawakami, Reiko Matsui, Hironori Fujii, Takanori Miyoshi, Tomoaki Eto, Makoto Kajizono, Tatsuya Ohtsubo, Yumi Morioka, Kyohei Yamaguchi, Akihiro Ogawa, Toshihisa Nakashima, Maki Todo, Koichi Matsuo Published: 2026 ABSTRACT AbstractIntroductionMaintaining dose intensity is essential for ensuring the efficacy of adjuvant S-1 chemotherapy in gastric cancer. Although pharmacist interventions can reduce toxicity and improve adherence, multicentre evidence regarding their impact on dose maintenance is limited.AimThis study aimed to evaluate the effectiveness of continuous pharmacist intervention on the eight-cycle treatment completion rate and relative performance (RP) in patients with gastric cancer undergoing outpatient S-1 adjuvant chemotherapy.MethodThis multicentre retrospective study analysed 225 patients across 12 institutions, categorised into the continuous intervention (n = 97) and non-continuous intervention (n = 128) groups. Continuous intervention was defined as systematic monitoring and management for at least 50% of the treatment duration. Inverse probability of treatment weighting was used to adjust for baseline covariates. The primary and secondary endpoints were the eight-cycle completion rate and RP value, respectively.ResultsThe eight-cycle completion rate did not differ significantly between the continuous and non-continuous intervention groups (53.0% vs. 55.2%, p = 0.775), nor did the frequency of treatment modification events, including discontinuation or dose reduction. However, the RP value was significantly higher in the continuous intervention group than in the non-continuous intervention group (73.7% vs. 64.9%, p = 0.038). This finding was robustly supported by sensitivity analysis between these two groups (75.1% vs. 61.1%, p = 0.0008). Overall, the continuous group maintained a high intervention rate (89.1%) throughout the final cycle, providing significantly more supportive care interventions than the non-continuous intervention group (53.2% vs. 4.9%, p < 0.001).ConclusionAlthough continuous pharmacist intervention did not improve the treatment completion rate, it was essential for maintaining RP values above the clinically essential 70% threshold through proactive toxicity management and dynamic dose optimisation. These findings suggest that systematic pharmaceutical care contributes significantly to ensuring the quality and intensity of adjuvant chemotherapy.Supplementary InformationThe online version contains supplementary material available at https://doi.org/10.1007/s11096-026-02200-5.Keywords: Adjuvant chemotherapy, Continuous intervention, Gastric cancer, Pharmacist, S-1 Impact statements Continuous pharmacist intervention during outpatient S-1 adjuvant chemotherapy may significantly contribute to maintaining adequate dose intensity, ensuring that patients with gastric cancer receive optimal treatment. Continuous pharmacist intervention during outpatient S-1 adjuvant chemotherapy may significantly contribute to maintaining adequate dose intensity, ensuring that patients with gastric cancer receive optimal treatment. Proactive and continuous pharmaceutical care, including the provision of tailored supportive care recommendations and timely dosage adjustment advice, facilitates better toxicity management and reduces the burden of adverse events on outpatients. Proactive and continuous pharmaceutical care, including the provision of tailored supportive care recommendations and timely dosage adjustment advice, facilitates better toxicity management and reduces the burden of adverse events on outpatients. These findings highlight the essential role of oncology pharmacists in multidisciplinary care teams, providing robust evidence to standardise and expand pharmacist-led ambulatory care programs in real-world clinical practice. These findings highlight the essential role of oncology pharmacists in multidisciplinary care teams, providing robust evidence to standardise and expand pharmacist-led ambulatory care programs in real-world clinical practice. Introduction Adjuvant chemotherapy is pivotal in improving treatment outcomes in patients with gastric cancer. Following the Adjuvant Chemotherapy Trial of TS-1 for Gastric Cancer (ACTS-GC trial) [1,2], which demonstrated the superiority of S-1 adjuvant chemotherapy over surgery alone for pStage II/III gastric cancer, this regimen became the standard of care in Japan. Subsequent studies expanded this evidence base, with domestic trials confirming its safety and efficacy [3–6]. The Japanese Gastric Cancer Treatment Guidelines (6th Edition) [7] strongly recommend adjuvant chemotherapy with S-1 for pStage II/III gastric cancer. Subgroup survival analysis from the ACTS-GC trial further highlighted the importance of completing 1 year of S-1 treatment with a relative performance (RP) of at least 70% [8,9]. The RP value is a measure of dose intensity over a 1-year adjuvant treatment period, as defined by the ACTS-GC trial [1]. This indicates that maintaining dose intensity and treatment completion are essential for optimising the therapeutic efficacy. S-1 is an oral fluoropyrimidine combination comprised of tegafur, gimeracil, and oteracil. Common adverse effects, including anorexia, nausea, diarrhoea, and fatigue, can hinder treatment continuation when persistent or severe, even if they are not high-grade. As this treatment is performed in the outpatient setting, appropriate prophylaxis and adverse-effect management, and support for medication adherence and self-care are crucial to ensuring uninterrupted treatment, indicating the importance of continuous pharmacist-led interventions to enhance pharmaceutical care. Recently, the critical role of oncology pharmacists in the provision of multidisciplinary care has been increasingly recognised worldwide. Recent systematic reviews [10,11] and clinical studies [12,13] have consistently demonstrated that pharmacist-led interventions significantly enhance medication adherence, resolve medication-related problems, and reduce the incidence of severe adverse events in patients with cancer. In Japan, initiatives, such as pharmacist-led outpatient clinics providing pre-consultation interviews, adverse-effect monitoring, and proposals for supportive care, are consequently being advanced. These programs are associated with improved treatment continuity and adherence, enhanced adverse effect management, reduced physician burden, and greater clinical efficiency [14–17]. However, most previous studies were small-scale, single-centre analyses, and evidence therefore remains limited. In particular, support systems for outpatient oral anticancer therapy vary considerably across institutions and nationwide standards are lacking. Multicentre studies involving diverse institutions are needed to evaluate the effectiveness and key components of pharmacist interventions in outpatient chemotherapy and to support their standardisation, broader implementation, and generalisability. Aim This study aimed to evaluate the effectiveness of continuous pharmacist intervention on the eight-cycle treatment completion rate and RP value in patients with gastric cancer receiving S-1 adjuvant chemotherapy as outpatients. Method Study design This multicentre, retrospective, observational study was conducted across 12 institutions, comprising three cancer centres, six general hospitals, and three university hospitals. The survey period spanned 24 months, from January 1, 2017, to December 31, 2018, to avoid the influence of changes in the medical system caused by the coronavirus disease pandemic. Patients who initiated S-1 adjuvant chemotherapy during this period were identified. Patients The inclusion criteria were: (1) age ≥ 20 years with a histologically confirmed gastric cancer diagnosis and receipt of S-1 monotherapy as adjuvant chemotherapy and (2) receipt of an initial S-1 dose determined by body surface area (BSA) in accordance with established guidelines. The initial dose of S-1 (80–120 mg/body/day, administered in two divided doses) was determined based on BSA as follows: 80 mg/day for BSA < 1.25 m2, 100 mg/day for BSA ≥ 1.25 to < 1.5 m2, and 120 mg/day for BSA ≥ 1.5 m2. The adjuvant S-1 regimen consisted of four consecutive weeks of oral administration, followed by a 2-week rest period, for a total of eight cycles. Patients concurrently enrolled in other clinical trials were excluded. Definition of pharmacist intervention and group assignment As this was a retrospective observational study, patients were not prospectively assigned or randomised to any specific intervention groups. Instead, all eligible patients were retrospectively categorised into two groups based on the frequency of pharmacist interventions during their S-1 adjuvant chemotherapy course. Pharmacist intervention was defined as actions extending beyond routine medication counselling to include systematic monitoring and adverse-event management, physician notification, and therapeutic recommendations. Although a baseline guidance session was mandatory, this initial encounter could be limited to treatment orientation alone. Furthermore, “continuous pharmacist intervention (continuous intervention group)” was defined as a clinical approach sustained for at least 50% of the total treatment duration (≥ 4 of 8 cycles); patients meeting this criterion were classified into the "continuous intervention group." All other patients, who received pharmacist interventions for less than 50% of their treatment duration (< 4 cycles), were classified into the "non-continuous intervention group." Endpoints The primary endpoint in this study was the treatment completion rate (8 cycles); this is the most objective and widely used indicator in both clinical practice and clinical trials. Secondary endpoints included treatment duration; RP value; treatment discontinuation; S-1 dose reduction; temporary interruption of S-1 treatment; prolongation of the S-1-free interval; unplanned hospitalisation; frequency of pharmaceutical interventions; and frequency of advice on treatment continuation or dose adjustment or supportive care recommendations for chemotherapy-induced nausea and vomiting (CINV), constipation, diarrhoea, oral mucositis, and hand‒foot syndrome. Although the RP value is strongly associated with clinical outcomes, we designated it as a secondary endpoint as it is a relatively new evaluation scale originally proposed in the ACTS-GC trial. The RP value was calculated using the following formula. Statistical analysis Rates of treatment completion, discontinuation, dose reduction, emergency hospitalisation, and supportive care prescriptions were compared between the two groups. To minimise confounding, propensity scores were calculated using a logistic regression model. We used the Inverse Probability of Treatment Weighting (IPTW) method to estimate the average treatment effect (ATE), defined as the average effect of the intervention if applied to the entire study population. Furthermore, stabilised weights (stabilised ATE) were applied to reduce the variance in the estimated treatment effect and minimise the influence of any extreme propensity scores. Notably, applying stabilised IPTW creates a balanced pseudo-population. Categorical and continuous variables were compared using chi-square test and Student’s t-test, respectively. Factors associated with high RP values were examined using multiple regression analysis. Sensitivity analysis was performed using overlap weighting. To address any residual imbalances remaining after IPTW adjustment, we applied the doubly robust (DR) method to analyse the treatment completion rate and RP values, incorporating the clinical department and prescription type as covariates. Adjusted odds ratios and their 95% confidence intervals (CIs) were calculated. Additionally, the adjusted treatment completion rates for each group and the corresponding p-value were estimated. All statistical tests were two-sided, and p-values < 0.05 indicated statistical significance. All analyses were performed using JMP 14.3 (SAS Institute, Cary, NC, USA). Ethics approval The study protocol was approved by the Institutional Review Boards of all participating institutions and the Ethics Committee of Fukuoka University (approval No. H23-08–007). All study procedures adhered to the principles of the Declaration of Helsinki. The Ethics Committee of Fukuoka University, the coordinating centre, waived the requirement for informed consent because of the study’s retrospective nature. Patient data were used after patients were given the option to decline participation via an opt-out form. Results Patient characteristics The study included 128 and 97 patients in the non-continuous and continuous intervention groups, respectively. Following adjustment using IPTW with stabilised weights to estimate the ATE, the generated pseudo-population yielded effective sample sizes of 135 and 86 for the non-continuous and continuous intervention groups, respectively. The increase in the patient count from 128 to an effective sample size of 135 in the non-continuous group occurred as a mathematical consequence of summing the stabilised weights within this pseudo-population. Most standardised mean differences (SMDs) for the key baseline characteristics were reduced, indicating well-balanced groups (Table 1, Supplementary Fig. 1). Serum creatinine levels, serum albumin levels, and pStage were all excluded from the model to prevent overfitting; however, following IPTW adjustment, these variables were appropriately balanced between the two groups, with serum creatinine levels (0.76 vs. 0.78; SMD = 0.103), serum albumin levels (3.86 vs. 3.89; SMD = 0.063), and stage II (vs. III) pStage (63.6% vs. 62.7%; SMD = 0.019) all remaining well balanced. Table 1Patient characteristicsUnadjustedAdjusted (Stabilised ATE)Non-continuousContinuousNon-continuousContinuousn%n%SMD%%SMD12897(ESS = 135)(ESS = 86)SexMale8667.25859.8 − 0.15463.465.30.04Female4232.83940.236.634.7Age, years ≥ 658264.17274.20.2272.572.90.009 < 654635.92525.827.527.1GastrectomyTotal4635.93839.20.06835.334.30.021Partial8264.15960.864.765.7Facility typeCancer centre5643.63132 − 0.24136.642.20.115General hospital or University hospital7256.4666863.457.8Clinical departmentSurgery7155.566.2 − 1.26232.424.70.171Internal medicine5744.59193.867.675.3PharmacistBoard-certified oncology pharmacist87684445.4 − 0.46862.568.30.122Non-certified41325354.637.531.7NurseBoard-certified oncology nurse4635.93030.9 − 0.1063239.20.151Non-certified8264.16769.16860.8Prescription typeOut-of-hospital9171.14041.2 − 0.63276.463.30.288In-hospital3728.95758.823.636.7ATE, average treatment effect; ESS, effective sample size; SMD, standardised mean difference Patient characteristics ATE, average treatment effect; ESS, effective sample size; SMD, standardised mean difference Duration of adjuvant chemotherapy The completion rate for eight cycles of adjuvant chemotherapy did not differ significantly between the non-continuous and continuous intervention groups (55.2% vs. 53.0%; p = 0.775). The median number of cycles was eight for both groups (interquartile ranges: 5–8 for the non-continuous intervention group, 4–8 for the continuous intervention group; p = 0.707); the mean number of cycles did not significantly differ between groups (6.0 vs. 5.6, p = 0.314) (Table 2). Table 2Duration of adjuvant chemotherapyNon-continuous intervention group(ESS = 135)Continuous intervention group(ESS = 86)p-valueTreatment completion (8 cycles), %55.253.00.775Total cycles administered, median (IQR)8 (5, 8)8 (4, 8)0.707Total cycles administered, mean ± SD6.0 ± 0.2345.6 ± 0.2920.314IQR, interquartile range; SD, standard deviation Duration of adjuvant chemotherapy IQR, interquartile range; SD, standard deviation RP value The RP value was significantly higher in the continuous intervention group than in the non-continuous intervention group (73.7 ± 3.31% vs. 64.9 ± 2.64%; p = 0.038) (Fig. 1). Comparison of relative performance values between non-continuous and continuous intervention groups The continuous intervention group (black bar) shows a significantly higher RP value (73.7 ± 3.31%) compared to the non-continuous intervention group (white bar, 64.9 ± 2.64%; p = 0.038). The dotted line indicates the RP value of 70%. RP, relative performance. Multiple regression analysis for factors associated with RP value “Continuous pharmacist intervention” was identified as a significant independent factor contributing to a higher RP value (B = 6.773, p = 0.016, 95% confidence interval: 1.274–12.272). In contrast, sex, age, gastrectomy type, facility type, clinical department, specialist certifications, and prescription type showed no significant associations with the RP value (Table 3). Table 3Multiple regression analysis for factors associated with high relative performance valueBβtp-value95% CISex (male vs. female) − 2.678 − 0.080 − 1.180.239 − 7.148–1.794Age (≥ 65 vs. < 65 years) − 2.098 − 0.061 − 0.880.382 − 6.819–2.623Gastrectomy (total vs. partial) − 1.282 − 0.039 − 0.570.569 − 5.712–3.149Facility type (cancer centre vs. general or university hospital) − 2.647 − 0.080 − 0.480.628 − 13.404–8.111Clinical department (surgery vs. internal medicine) − 0.550 − 0.016 − 0.140.887 − 8.134–7.034Pharmacist (certified vs. non-certified) − 2.766 − 0.085 − 0.790.433 − 9.705–4.174Nurse (certified vs. non-certified)4.2450.1250.700.486 − 7.751–16.241Prescription (out-of-hospital vs. in-hospital) − 4.894 − 0.150 − 1.790.074 − 10.270–0.482Pharmacist intervention (continuous vs. non-continuous)6.7730.2092.430.0161.274–12.272B, unstandardised coefficient (Beta); β, standardised partial regression coefficient (standardised beta); CI, confidence interval Multiple regression analysis for factors associated with high relative performance value B, unstandardised coefficient (Beta); β, standardised partial regression coefficient (standardised beta); CI, confidence interval Factors leading to treatment modification or discontinuation No significant differences were found between the non-continuous and continuous intervention groups in the treatment discontinuation rate, S-1 dose reduction, temporary treatment interruption, S-1-free interval prolongation, or unplanned hospitalisation, whether for all-cause or adverse event-related factors. Although unplanned hospitalisation tended to occur more frequently in the continuous intervention group than in the non-continuous intervention group (12.5% vs. 5.3%, p = 0.054), this trend was not significant. The rates of discontinuation (16.1% vs. 14.2%) and dose reduction (28.3% vs. 29.8%) specifically due to adverse events were also comparable between groups (Supplementary Table 1). Breakdown of pharmaceutical interventions The mean number of interventions per patient was significantly higher in the continuous intervention group (2.34 ± 0.005) than in the non-continuous intervention group (1.21 ± 0.037) (p < 0.001). Further, the rate of supportive care interventions was significantly higher in the continuous intervention group (53.2%) than in the non-continuous intervention group (4.9%) (p < 0.001) (Table 4). Specifically, interventions for CINV (26.9% vs. 6.2%), constipation (7.9% vs. 1.4%), diarrhoea (20.1% vs. 6.1%), oral mucositis (17.5% vs. 0%), and hand‒foot syndrome (10.0% vs. 0.4%) were significantly more frequent in the continuous intervention group than in the non-continuous intervention group (all p < 0.05) (Supplementary Table 2). Table 4Pharmaceutical interventionsNon-continuous intervention group(ESS = 135)Continuous intervention group(ESS = 86)p-valueAverage number of interventions, mean ± SD1.21 ± 0.0372.34 ± 0.005 < 0.001Intervention detailsSupportive care recommendations, %4.953.2 < 0.001Advice on treatment continuation or dose adjustment, %9.025.0 < 0.001ESS, effective sample size; SD, standard deviation Pharmaceutical interventions ESS, effective sample size; SD, standard deviation Pharmaceutical interventions by treatment cycle In the non-continuous intervention group, interventions were performed from the first (47.4%) to the third cycle (11.0%) but decreased to 0% from the fourth cycle onwards. In contrast, the continuous intervention group maintained a high intervention rate throughout all cycles, from the first (100%) to the eighth cycle (89.1%). Interventions regarding supportive care and treatment continuation/dosage adjustment were also consistently implemented across all cycles in the continuous group (Table 5). Table 5Pharmaceutical interventions by treatment cycle from cycle 1 to 8 (C1‒C8)C1C2C3C4C5C6C7C8ESSNon-continuous group1351201099995858274Continuous group8676635854504846Overall intervention rate per cycle (%)Non-continuous group47.415.011.000000Continuous group10084.293.798.396.392.089.689.1Breakdown of pharmaceutical interventionSupportive care recommendations (%)Non-continuous group1.54.2000000Continuous group33.730.319.015.511.14.02.12.2Advice on treatment continuation or dose adjustment (%)Non-continuous group8.96.7000000Continuous group11.610.56.38.65.64.02.14.3ESS, effective sample size Pharmaceutical interventions by treatment cycle from cycle 1 to 8 (C1‒C8) ESS, effective sample size Sensitivity analysis To assess the robustness of the primary findings, sensitivity analysis was performed using overlap weighting. This method achieved a perfect balance for all baseline covariates, with an SMD of 0 and an effective sample size of 32 for each group (Supplementary Table 3). The eight-cycle completion rate (58.1% vs. 59.2%, p = 0.993) and median number of cycles (8 for both groups, p = 0.707) did not significantly differ between groups (Supplementary Table 4. However, the RP value was significantly higher in the continuous intervention group (75.1 ± 2.91%) than in the non-continuous intervention group (61.1 ± 2.92%) (p = 0.0008) (Supplementary Table 5. The mean number of interventions was significantly higher in the continuous intervention group (2.412 ± 0.043) than in the non-continuous intervention group (1.169 ± 0.043), with a notably higher rate of interventions related to continuation or dosage adjustment in the continuous intervention group (53.5% vs. 3.3%, p < 0.001). These findings were consistent with those observed in the main analysis (Supplementary Table 6). Furthermore, we further performed DR analysis to address any residual imbalances after IPTW adjustment (e.g. clinical department, prescription type), which yielded results consistent with the main analysis. Overall, the RP value was significantly higher in the continuation group than the non-continuation group (72.81% vs. 64.06%; p = 0.007), while adjusted treatment completion odds did not significantly differ between the groups (OR: 1.233, 95% CI: 0.648–2.344). Discussion In the present study, the primary endpoint, the 8-cycle completion rate did not significantly differ between the continuous and non-continuous intervention groups. However, the secondary endpoint, RP value was significantly higher in the continuous intervention group. This difference may be attributed to the nature of the pharmacists’ interventions. Pharmacists proactively monitored adverse events and often recommended timely dose reductions or temporary interruptions, rather than complete treatment discontinuation. Furthermore, pharmacists actively proposed the provision of supportive care to physicians, including antiemetics, antidiarrheal agents, topical ointments and mouthwashes for stomatitis, and moisturizers and topical corticosteroids for hand-foot syndrome, with most of these recommendations accepted. This "dynamic dose optimization" enabled patients to continue therapy for a longer duration, thereby maintaining a higher cumulative RP value. Although previous studies, such as the ACTS-GC trial [1], have demonstrated that maintaining an RP ≥ 70% is a critical surrogate marker for improved survival, our study did not directly assess the long-term survival outcomes. Therefore, the clinical benefit associated with the maintained RP value should be interpreted with caution until it can be confirmed by prospective survival data. Although Kimura et al. [16] reported significant improvements in completion rates through pharmacist intervention, the lack of significant differences in the present study may reflect differences in intervention definition. Although the previous study focused on "the presence or absence of initial consultation," we evaluated "continuity throughout the treatment period," which may have resulted in a smaller impact on completion rate as a binary outcome measure. Interestingly, we observed a trend towards an increased rate of unplanned hospitalisations in the continuous intervention group. Although this finding may suggest reverse causality, in which patients experiencing greater toxicity burdens naturally require and receive more frequent pharmacist interventions, the risk of such reverse causality was considered low in our study cohort. Indeed, the categorisation of patients into the continuous or non-continuous intervention groups was predominantly driven by institutional factors, specifically the availability of pharmacist manpower at each facility, rather than by individual patient conditions, such as poor general health or adherence. Consequently, interventions were predominantly based on each facility’s operational capacity. Therefore, the observed trend in unplanned hospitalisations likely reflects proactive admissions due to more rigorous monitoring and earlier detection of severe adverse events by pharmacists, rather than reverse causality. Importantly, “continuous pharmacist intervention” was identified as a significant independent factor associated with higher RP values, thus supporting the critical role of systematic continuity of care in maintaining treatment intensity. Although interventions in the non-continuous intervention group nearly ceased following the third cycle, the continuous group maintained a high intervention rate through the final cycle. Even low-grade (Grade 1–2) cumulative toxicities can significantly impair patients’ quality of life, potentially resulting self-initiated non-adherence or "patient-led" treatment gaps [18–22]. For example, gastrointestinal toxicities significantly contribute to medication non-adherence and treatment discontinuation during capecitabine- and S-1-based regimens. Our results align with recent literature highlighting the value of pharmacist involvement [11,19,21,23,24]. The randomised AMBORA trial [13] and a meta-analysis by Fentie et al. [11] previously demonstrated that intensive pharmaceutical care significantly reduces adverse drug events and overall drug-related problems, while substantially improving treatment adherence. Furthermore, pharmacist-led remote monitoring programs and outpatient clinics have proven effective at both resolving drug-related problems and reducing unplanned healthcare utilisation [24–27]. As designing multifaceted interventions is essential for patients receiving oral anticancer drug therapy, the present study indicates that pharmacists help to maintain the overall dose intensity by continuously monitoring adverse events, providing supportive care recommendations, and adjusting treatment regimens. This study has some limitations. First, unmeasured confounders, such as performance status, comorbidities, and the baseline risk of toxicity, may have influenced both pharmacist involvement and S-1 tolerability, resulting in potential residual confounding despite the propensity score adjustment. Second, although the threshold of ≥ 50% for “continuous intervention” reflects the Japanese medical reimbursement system and real-world clinical practice, it remains somewhat arbitrary. Because detailed data on the exact number of intervention cycles for each patient were unavailable, sensitivity analyses addressing the within-group heterogeneity of this factor could not be performed. Third, a priori sample size calculation was not performed because of the retrospective observational study design. The lack of any significant difference in the primary endpoint (8-cycle completion rate) may also be partly due to the study being underpowered. Finally, although further subgroup analyses (e.g., by clinical department or prescription setting) were considered, stratifying the cohort resulted in sample sizes too small to yield statistically reliable conclusions. Future large-scale, prospective studies are therefore warranted to address these limitations. Furthermore, although the RP value is an established predictor of prognosis, further research is required to evaluate the long-term impact of pharmacist interventions on definitive clinical outcomes, such as overall survival and recurrence-free survival. Nevertheless, our findings demonstrate that maintaining a clinically meaningful dose intensity through continuous pharmacist involvement is a pivotal strategy for improving the quality of adjuvant chemotherapy. Conclusion Overall, the present study found that continuous pharmacist intervention did not significantly improve the eight-cycle treatment completion rate, but was associated with significantly higher RP, likely by facilitating proactive toxicity management and dynamic dose optimisation to maintain a higher cumulative dose intensity. As RP is a surrogate marker and long-term survival was not assessed, further prospective studies are warranted to confirm whether these improvements translate into clinical benefits, such as prolonged survival. Supplementary Information Below is the link to the electronic supplementary material. Supplementary file1 (JPG 273 kb) Supplementary file2 (DOCX 25 kb)